Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: September 13, 2005
Last updated: September 20, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2005
  Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):